Spago Nanomedical AB

As of June 30, 2026, Spago Nanomedical AB carries a market capitalization of 93.01M, placing it among publicly traded companies globally. Its enterprise value stands at 60.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Spago Nanomedical AB's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Spago Nanomedical AB has 798.38M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Spago Nanomedical AB maintains a current ratio of 7.25, meaning it holds 7.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Spago Nanomedical AB's stock has declined approximately 37.65% over the past 52 weeks. The 50-day moving average sits at 0.11, while the 200-day moving average is 0.11.

These figures are as of June 30, 2026. Total book value stands at 31.67M, with working capital of 31.75M providing operational flexibility.

Spago Nanomedical AB's most recent stock split took place on May 28, 2026.